Search Results - "Morani, Gabriele"

Acid sensing ion channel 2: A new potential player in the pathophysiology of multiple sclerosis by Fazia, Teresa, Pastorino, Roberta, Notartomaso, Serena, Busceti, Carla, Imbriglio, Tiziana, Cannella, Milena, Gentilini, Davide, Morani, Gabriele, Ticca, Anna, Bitti, Pierpaolo, Berzuini, Carlo, Dalmay, Tamas, Battaglia, Giuseppe, Bernardinelli, Luisa

“…Acid‐sensing ion channels (ASICs) are proton‐gated channels involved in multiple biological functions such as: pain modulation, mechanosensation,…”
Get full text

Genetic Determinants of Lipids and Cardiovascular Disease Outcomes: A Wide-Angled Mendelian Randomization Investigation by Allara, Elias, Morani, Gabriele, Carter, Paul, Gkatzionis, Apostolos, Zuber, Verena, Foley, Christopher N, Rees, Jessica M B, Mason, Amy M, Bell, Steven, Gill, Dipender, Lindström, Sara, Butterworth, Adam S, Di Angelantonio, Emanuele, Peters, James, Burgess, Stephen

“…Evidence from randomized trials has shown that therapies that lower LDL (low-density lipoprotein)-cholesterol and triglycerides reduce coronary artery disease…”
Get full text

Abstract PD15-02: HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer by Sirvén, Milana A Bergamino, López-Knowles, Elena, Morani, Gabriele, Tovey, Holly, Kilburn, Lucy, Holcombe, Chris, Skene, Anthony, Smith, Ian, Robertson, John, Schuster, Gene, Bliss, Judith M, Dowsett, Mitch, Cheang, Maggie CU

“…Background: Approximately 10% of estrogen receptor positive (ER+) early breast cancers (EBC) are human epidermal growth factor positive/overexpressed (HER2+)…”
Get full text

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers by Bergamino, Milana A, Morani, Gabriele, Parker, Joel, Schuster, Eugene F, Leal, Mariana F, López-Knowles, Elena, Tovey, Holly, Bliss, Judith M, Robertson, John F R, Smith, Ian E, Dowsett, Mitch, Cheang, Maggie C U

“…Aromatase inhibitor (AI) treatment is the standard of care for postmenopausal women with primary estrogen receptor-positive breast cancer. The impact of…”
Get full text

Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry by Milighetti, Martina, Krasny, Lukas, Lee, Alex T.J., Morani, Gabriele, Szecsei, Cornelia, Chen, Yingtong, Guljar, Nafia, McCarthy, Frank, Wilding, Christopher P., Arthur, Amani, Fisher, Cyril, Judson, Ian, Thway, Khin, Cheang, Maggie C.U., Jones, Robin L., Huang, Paul H.

“…Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic and epigenomic profiling of STS have been undertaken,…”
Get full text

Abstract P2-03-07: Multi-parametric algorithm integrating on-treatment Ki67 value and standard clinicopathological variables to predict risk of recurrences for women > 70 years old with early ER+HER2- tumours in POETIC trial by Cheang, Maggie Chon U, Dewan, Monisha, Kilburn, Lucy, Morani, Gabriele, Zabaglo, Lila, Sidhu, Kally, Tovey, Holly, Zhu, Xixuan, Holcombe, Chris, Skene, Anthony, Smith, Ian, Robertson, John, Ring, Alistair, Turner, Nicholas, Bliss, Judith, Dowsett, Mitch

“…Background: Prognosis in older patients with breast cancer (BC) is worse compared to younger patients. No robust and specific tool to predict the risk of…”
Get full text